How much funding has Claris Bio raised?

Claris Bio has raised $118.0M in total funding, most recently a Series B round.

What industry is Claris Bio in?

Claris Bio operates in Biotech, Healthcare.

Claris Bio

Q: Who are Claris Bio's investors?

Claris Bio's investors include Samsara BioCapital, Catalio Capital Management, Adage Capital.

Limbal stem cell deficiency (LSCD) | CSB-001

Biotech

Healthcare

Website: clarisbio.com
Total Funding: $118.0M

Last Round: $118.0M Series BAug 2026
Rounds: 1

About

Claris Bio is a biopharmaceutical company developing therapies for sight-threatening corneal diseases with limited or no treatment options. Its lead investigational program, CSB-001, is an ophthalmic solution for limbal stem cell deficiency. The company focuses on improving outcomes for patients with corneal conditions, including wounds, ulcers, and scarring.

Summary

Claris Bio is a Biotech company. It has raised $118.0M in total across 1 round, most recently a $118.0M Series B round in Aug 2026. Investors include Samsara BioCapital, Catalio Capital Management and Adage Capital.